Quarterly report · Q2
6095.TEDINET S100QPSY
Period2022-10-01 → 2023-03-31
Filed2023-05-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥7.1bn | 2022-10-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥8.5bn | 2021-10-01 → 2022-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.4bn | 2021-10-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥717m | 2022-10-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥867m | 2021-10-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥735m | 2022-10-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.1bn | 2021-10-01 → 2022-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥890m | 2021-10-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥735m | 2022-10-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥890m | 2021-10-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥380m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥812m | 2021-10-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥599m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥391m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥618m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥14.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥9.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥9.2bn | at 2022-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.8bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.5bn | at 2022-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥8.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥7.6bn | at 2022-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.1bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.1bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.7bn | at 2021-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥122m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥853m | 2021-10-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥538m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.8bn | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥423m | 2021-10-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥78m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥4.2bn | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥7m | 2021-10-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥21m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥17.42 | 2022-10-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.62 | 2021-10-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.74 | 2021-10-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.57 | 2022-01-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥17.05 | 2022-10-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥35.78 | 2021-10-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.26 | 2021-10-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 57.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-10-01 → 2023-03-31 | −¥5m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-10-01 → 2023-03-31 | −¥5m |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2023-03-31 | −¥657m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥5.7bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥5.7bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥2m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | segment profit | 2022-10-01 → 2023-03-31 | ¥1.3bn |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥243m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥240m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥3m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2022-10-01 → 2023-03-31 | −¥40m |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥300,000 |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | segment profit | 2022-10-01 → 2023-03-31 | ¥94m |
| —segment total | revenue | 2022-10-01 → 2023-03-31 | ¥7.1bn |
| —segment total | revenue external | 2022-10-01 → 2023-03-31 | ¥7.1bn |
| —segment total | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥5m |
| —segment total | segment profit | 2022-10-01 → 2023-03-31 | ¥1.4bn |
| Reconciling Itemsreconciling | revenue | 2021-10-01 → 2022-03-31 | −¥7m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-10-01 → 2022-03-31 | −¥7m |
| Reconciling Itemsreconciling | segment profit | 2021-10-01 → 2022-03-31 | −¥645m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥3.2bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥3.2bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥2m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥1.3bn |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥202m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥199m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥3m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥30m |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥1.0bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥1.0bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥3m |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥137m |
| —segment total | revenue | 2021-10-01 → 2022-03-31 | ¥4.4bn |
| —segment total | revenue external | 2021-10-01 → 2022-03-31 | ¥4.4bn |
| —segment total | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥7m |
| —segment total | segment profit | 2021-10-01 → 2022-03-31 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 506
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of intangible assets inv cf | CurrentYTDDuration | -28432000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | － | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -120508000 | JPY |
| Payments for lease and guarantee deposits inv cf | Prior1YTDDuration | -10000 | JPY |
| Payments for lease and guarantee deposits inv cf | CurrentYTDDuration | － | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | CurrentYTDDuration | 79000 | JPY |
| Collection of loans receivable inv cf | Prior1YTDDuration | － | JPY |
| Collection of loans receivable inv cf | CurrentYTDDuration | 1015000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YTDDuration | － | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYTDDuration | -4648102000 | JPY |
| Other net inv cf | Prior1YTDDuration | 669000 | JPY |
| Other net inv cf | CurrentYTDDuration | 3062000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -78458000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -4796727000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | － | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | 4200000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -28068000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -293300000 | JPY |
| Proceeds from issuance of common stock fin cf | Prior1YTDDuration | 7848000 | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYTDDuration | 338015000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | － | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -66000 | JPY |
| Other net fin cf | Prior1YTDDuration | -858000 | JPY |
| Other net fin cf | CurrentYTDDuration | -875000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -21078000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 4243773000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 438153000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -430642000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 5701332000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 6138758000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 6139486000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 5708116000 | JPY |
| Directors compensations sga | Prior1YTDDuration | 124587000 | JPY |
| Directors compensations sga | CurrentYTDDuration | 146720000 | JPY |
| Compensations salaries and allowances sga | Prior1YTDDuration | 459988000 | JPY |
| Compensations salaries and allowances sga | CurrentYTDDuration | 873284000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 55831000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 64433000 | JPY |
| Provision for directors bonuses sga | Prior1YTDDuration | 3997000 | JPY |
| Provision for directors bonuses sga | CurrentYTDDuration | 2419000 | JPY |
| Advertising expenses sga | Prior1YTDDuration | 105504000 | JPY |
| Advertising expenses sga | CurrentYTDDuration | 78760000 | JPY |
| Point card certificates expenses sga | Prior1YTDDuration | 273073000 | JPY |
| Point card certificates expenses sga | CurrentYTDDuration | 282679000 | JPY |
| Provision for point card certificates sga | Prior1YTDDuration | 1321000 | JPY |
| Provision for point card certificates sga | CurrentYTDDuration | -8183000 | JPY |
| Commission fee sga | Prior1YTDDuration | 338208000 | JPY |
| Commission fee sga | CurrentYTDDuration | 369997000 | JPY |
| Amortization of goodwill sga | Prior1YTDDuration | 18414000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |